Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985730 | 1.00 | AR (0.46) | ARCHEK2KIF11RAF1KDR | |
| SCHEMBL24181308 | 0.85 | KIF11 (0.50) | ARKIF11ALDH1A1PARP10PARP3 | |
| SCHEMBL876324 | 0.84 | AR (0.46) | ARCHEK2RAF1KDRBRAF | |
| SCHEMBL29984723 | 0.84 | AR (0.46) | ARCHEK2RAF1KDRBRAF | |
| SCHEMBL883449 | 0.84 | CHEK2 (0.46) | ARCHEK2RAF1KDRBRAF | |
| SCHEMBL9101725 | 0.83 | SCN9A (0.47) | ARKIF11RAF1KDRBRAF | |
| SCHEMBL876289 | 0.83 | CHEK2 (0.47) | ARCHEK2RAF1KDRBRAF | |
| SCHEMBL1283899 | 0.83 | KIF11 (0.51) | ARKIF11KDRBRAFCDK8 | |
| SCHEMBL9103130 | 0.82 | PLA2G7 (0.47) | SCN9A | |
| SCHEMBL29851798 | 0.82 | PLA2G7 (0.47) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-114057740-B | Spiropyrimidinone derivatives, method for the production thereof, pharmaceutical compositions and use thereof | 上海赛默罗生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4324835-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-115925721-A | Pyrimidone tricyclic derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022233302-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | 上海赛默罗生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| CN-115304620-A | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114057740-A | Spirocyclic pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | AR 1513/4885CHEK2 4153/4885KIF11 4823/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AR 22/4885CHEK2 2929/4885KIF11 4690/4885 |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | PLA2G1B, LYPLAL1, PLA2G12B | AR 2378/4885CHEK2 4462/4885KIF11 2694/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AR 25/4885CHEK2 2982/4885KIF11 4736/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | AR 3764/4885CHEK2 12/4885KIF11 4422/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AR 25/4885CHEK2 2982/4885KIF11 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.